Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Figure 5

Additive antitumor activity of dasatinib and Eto in MDA-MB-157 cells. The cells were treated with indicated concentrations of Eto and/or 0.1 μM dasatinib for three days. Dasatinib additively inhibited the growth of MDA-MB-157 cells. Open circles represent values treated with Eto alone. Closed circles represent values treated with Eto plus dasatinib. The values are expressed as mean ± S.E. of at least two separate experiments.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us